Events


Journal Clubs

11 a.m.-noon
PACT 811

Journal Clubs occur every other Thursday beginning Jan. 5, 2017.


Seminars

Friday, Sept. 29, 2017
1:00 p.m. – 2:00 p.m.
AHSP PEC 8

A Special BIRI Seminar
Lead compound discovery and optimization, on the example of CXCR4; spectroscopic MRI for the management of GBM patients

Speaker: Hyunsuk Shim, PhD, Professor and Scientific Director, Department of Radiation Oncology at Emory University


Grand Rounds

October 3, 2017
12:00 p.m. – 1:00 p.m.
AHSP PEC 8

Cancer Nanotheranostics

Speaker: Xiaoyuan (Shawn) Chen, PhD, Senior Investigator at the National Institute of Biomedical Imaging and Bioengineering National Institutes of Health

Abstract

Theranostics (Rx/Dx) aims to develop molecular diagnostic tests and targeted therapeutics with the goals of individualizing treatment by targeting therapy to an individual's specific disease subtype and genetic profile. It can be diagnosis followed by therapy to stratify patients who will likely respond to a given treatment; it can also be therapy followed by diagnosis to monitor early response to treatment and predict treatment efficacy; it is also possible that diagnostics and therapeutics are co-developed (nanotheranostics). This talk will give examples of optotheranostics, magnetotheranostics and immunotheranostics. The translational potential of Nanotheranostics will also be briefly discussed.

July 18, 2017
9-10 a.m.
ECC-B

Molecular Imaging for the Improved Visualization and Treatment of Cancer

Speaker: Jason S. Lewis, PhD, professor and Emily Tow Chair in oncology at Memorial Sloan Kettering Cancer Center, NY

Abstract:

Positron emission tomography (PET) for cancer imaging is a well-established and widely used molecular imaging modality both in clinical and research settings. PET offers the ability to quantitatively measure biological and receptor-based processes using a wide spectrum of specifically designed radiopharmaceuticals. The use of PET is expanding, and the inclusion of longer-lived radiometal positron-emitters is broadening the application and appeal of this imaging modality.

Dr. Lewis' research interests are focused on the development of new PET radiopharmaceuticals for the diagnosis and treatment of cancer. His work incorporates F-18, C-11, and nonstandard nuclide radiopharmaceutical development, with an emphasis on cancer detection and therapy. The Lewis Lab works on the development of small molecules, radiolabeled peptides and antibodies that target the overexpression of receptors and antigens on tumors as well as imaging changes in the tumor microenvironment associated with malignancy.

May 4, 2017
12:00 p.m. – 1:00 p.m.
Davis 1004

ImmunoPET: Engineered antibodies for profiling tumors and immune responses

Speaker: Anna M. Wu, PhD, professor and vice chair, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Faculty, Crump Institute for Molecular Imaging

Abstract: Antibodies provide a versatile platform for noninvasive imaging of cells and tissues based on cell surface phenotype. We have developed engineered antibody fragments (minibody and diabody) with accelerated clearance properties, optimized for in vivo targeting and imaging.

When labeled with positron-emitting radionuclides (such as I-124, Zr-89, Cu-64, F-18), engineered fragments can be employed for high resolution, sensitive, quantitative imaging by PET (positron emission tomography) and provide highly specific molecular assessments of tumor biology and response to treatment.

For example, an I-124 prostate stem cell antigen (PSCA)-specific minibody demonstrates highly specific imaging in mouse models of prostate cancer and provides a PET imaging readout of response to enzalutamide treatment. ImmunoPET can be extended to the detection of cell surface markers on immune cell subsets such as CD4 or CD8 on T lymphocytes and CD20 on B lymphocytes, providing a means for assessing immune cell subsets.

Applications include imaging CD 8 and CD 4 T lymphocyte repopulation following stem cell transplantation, and monitoring CD8 cytotoxic T cell infiltration into tumors in cancer immunotherapy (e.g. treatment with anti-4-1BB or anti-PD-L1 antibodies, and adoptive transfer of OT-I T lymphocytes) in syngeneic mouse models. More recently, immunoPET has been extended to detection of CD4 T lymphocyte expansion in a model of inflammatory colitis.

ImmunoPET provides a broad approach for noninvasive, whole-body monitoring of key factors such as target expression in vivo, response to therapy, and immune responses. Furthermore, this approach is highly translatable, and stands to play an expanding role in the detection and management of cancer and other diseases.

March 10, 2017
10-11 a.m.
PEC 6-7

Probing Tumor Heterogeneity Using Advanced Diffusion Imaging

Speaker: Xiaohong Joe Zhou, PhD, director, Center for MR Research and professor, departments of Radiology and Bioengineering, University of Illinois

Abstract: Intra-tumor heterogeneity has been identified as one of the most important factors in making accurate diagnoses and tailoring therapy to individual patients. Tumor heterogeneity arises from a variety of origins such as genetics, epigenetics, physiology, and pathology, all of which lead to structural heterogeneity at a specific spatial scale.

Characterization of tumor structural heterogeneity can thus provide a unique avenue to probe the underlying biological processes and improve cancer patient care. Unfortunately, the current spatial resolution (e.g., hundreds of micrometer to a few millimeter) for human MRI is far from adequate to identify tissue structural heterogeneity at a microscopic level (e.g., ~5-50 micrometer).

Efforts to further improve the resolution face formidable technical challenges. An alternative strategy is to rely on the present spatial resolution, but focus on extracting sub-voxel information by linking a macroscopic voxellevel measurement to a microscopic intra-voxel physical process that reflects tissue structural heterogeneity.

Using a novel diffusion model based on continuous-time random walk (CTRW) and its associated fractional order calculus (FROC), our group has observed an increasing number of evidences suggesting a strong link between voxellevel macroscopic anomalous diffusion parameters and microscopic sub-voxel tissue heterogeneity.

This presentation will describe the CTRW and FROC diffusion models, illustrate the associated diffusion imaging techniques, and demonstrate a number of clinical applications. In these applications, anomalous diffusion parameters have been found useful to probe tumor heterogeneity at a sub-voxel level to improve diagnostic accuracy or predict cancer response to targeted therapy.

 

Related Events

Jan. 20-22, 2017
Harvey Morse
Conference Center

Cedars-Sinai Advances in Nuclear Cardiology and Cardiac CT: Annual Case Review With the Experts With 101 Evidence-Based Cases

Daniel S. Berman, MD, FACC, FSCCT
Guido Germano, PhD, MBA, FACC
James Min, MD, FACC, FSCC
Learn more and register

See a list of previous BIRI events.